Understand this story
Novoprotein issued a stock trading abnormal fluctuation announcement on November 1, 2026, stating that its AI-empowered high-throughput wet lab and data package services are still in the early stage of market expansion, and that as of the third quarter of 2026, revenue from the related business accounted for less than 2% of the company's total operating revenue. The company also cautioned that the application of AI in the drug R&D industry is still in its infancy, and that risks exist, including rapid technological iteration, long industry validation cycles, and significant difficulty in commercial implementation, with major uncertainty regarding future realization of related revenue and profits. Previously, the company's stock closing price rose by a cumulative deviation of more than 30% over three consecutive trading days from October 28 to 30, triggering the abnormal fluctuation. A subsequent report by East Money supplemented that the company's net profit attributable to shareholders for the first three quarters of 2026 was -47.9034 million yuan, an increased loss of 19.0441 million yuan year-on-year; as of the close on October 30, its price-to-sales ratio (TTM) was 66.18, significantly higher than that of comparable companies in the same industry, and its stock price had cumulatively risen 276.53% from the beginning of the year to October 30.
AI-generated from public reports
Latest development · Report
Novoprotein notes AI-related services account for less than 2% of revenue; shares up 276.53% year to dateDevelopments
1 confirmed developments
Reports and discussion timeline
Browse reports and discussion by time. Their evidence levels remain distinct.
Nov 2
East Money
Novoprotein notes AI-related services account for less than 2% of revenue; shares up 276.53% year to date
Novoprotein issued an announcement on November 1 regarding abnormal fluctuations in its stock trading, stating that the "AI-empowered high-throughput wet-lab experiments and data package services" that have drawn market attention are still in the early stages of market development, and that as of the third quarter of 2026, related revenue accounted for less than 2% of total operating revenue. The company's net profit attributable to shareholders for the first three quarters of 2026 was -47.9034 million yuan, an increased loss of 19.0441 million yuan year-on-year; as of the close on October 30, its price-to-sales ratio (TTM) was 66.18, significantly higher than that of comparable companies in the same industry. From the beginning of the year to October 30, the stock price rose 276.53% cumulatively.
Nov 1
Yicai
Novoprotein: Its high-throughput wet-lab and data package services that empower AI are still in the early stage of market expansion, with related revenue accounting for less than 2%
Novoprotein announced that its high-throughput wet-lab and data package services that empower AI are still in the early stage of market expansion, and as of the third quarter of 2026, revenue from related businesses accounted for less than 2% of the company's total operating revenue. The company cautioned that the application of AI in the drug R&D industry is still in its infancy, and there are risks such as rapid technological iteration, long industry validation cycles, and significant difficulty in commercial implementation, and future realization of related revenue and profits is subject to major uncertainty. Previously, the company's stock price rose by a cumulative deviation of more than 30% over three consecutive trading days from October 28 to 30, constituting an abnormal fluctuation in stock trading.